

Debabrata Mukherjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4852348/publications.pdf>

Version: 2024-02-01

366
papers

34,445
citations

17405

63
h-index

3714

179
g-index

379
all docs

379
docs citations

379
times ranked

28932
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
2	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
3	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
4	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
5	Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 954.	3.8	1,497
6	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	1.2	1,232
7	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016, 134, e123-55.	1.6	1,069
8	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
9	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
10	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1200-1254.	1.2	706
11	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1235-1250.	1.2	684
12	Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2414.	3.8	602
13	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
14	Acute Intramural Hematoma of the Aorta. <i>Circulation</i> , 2005, 111, 1063-1070.	1.6	457
15	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	1.2	424
16	Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2001, 104, 2767-2771.	1.6	411
17	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2016, 133, 1135-1147.	1.6	403
18	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1502-1517.	1.2	390

#	ARTICLE	IF	CITATIONS
19	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2427-2463.	1.2	352
20	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. <i>Journal of the American College of Cardiology</i> , 2021, 78, e187-e285.	1.2	336
21	Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 1428-1434.	0.7	333
22	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 144, e368-e454.	1.6	319
23	Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 745-749.	1.6	287
24	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1243-1275.	0.4	249
25	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2663-2699.	1.2	244
26	Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. <i>BMJ</i> , The, 2013, 346, f55-f55.	3.0	232
27	Peripheral Arterial Disease in Patients With End-Stage Renal Disease. <i>Circulation</i> , 2006, 114, 1914-1922.	1.6	229
28	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. <i>Diabetes Care</i> , 2010, 33, 1395-1402.	4.3	211
29	Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts. <i>Circulation</i> , 2002, 106, 3063-3067.	1.6	201
30	Direct myocardial revascularization and angiogenesis—how many patients might be eligible?. <i>American Journal of Cardiology</i> , 1999, 84, 598-600.	0.7	199
31	Diabetic cardiomyopathy - A comprehensive updated review. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 315-326.	1.6	197
32	Association of Blood Transfusion With Increased Mortality in Myocardial Infarction. <i>JAMA Internal Medicine</i> , 2013, 173, 132.	2.6	196
33	Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 341-351.	1.1	194
34	Mitral valve surgery in patients with severe left ventricular dysfunction. <i>European Journal of Cardio-thoracic Surgery</i> , 2000, 17, 213-221.	0.6	176
35	A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. <i>Scientific Reports</i> , 2021, 11, 8562.	1.6	175
36	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 453-495.	0.7	157

#	ARTICLE	IF	CITATIONS
37	Liver Abnormalities in Cardiac Diseases and Heart Failure. <i>International Journal of Angiology</i> , 2011, 20, 135-142.	0.2	156
38	Effect of Clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. <i>American Journal of Cardiology</i> , 2001, 88, 672-674.	0.7	144
39	Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. <i>Journal of Vascular Surgery</i> , 2004, 39, 357-365.	0.6	142
40	Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1678-1686.	1.2	127
41	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 259-352.	2.3	125
42	Missed Opportunities to Treat Atherosclerosis in Patients Undergoing Peripheral Vascular Interventions. <i>Circulation</i> , 2002, 106, 1909-1912.	1.6	123
43	Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2007, 100, 1-6.	0.7	122
44	Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2266-2275.	1.2	122
45	Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. <i>Biochemical Pharmacology</i> , 2002, 63, 817-821.	2.0	118
46	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2550-2583.	1.2	114
47	Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. <i>International Journal of Angiology</i> , 2007, 16, 36-36.	0.2	107
48	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 144, e368-e454.	1.6	99
49	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E266-355.	0.7	97
50	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2878-2886.	1.2	96
51	Pharmacologic Rate versus Rhythm Control Strategies in Atrial Fibrillation: An Updated Comprehensive Review and Meta-Analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 122-133.	0.5	90
52	Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2004, 147, 42-48.	1.2	89
53	Comparison of Results of Carotid Stenting Followed by Open Heart Surgery Versus Combined Carotid Endarterectomy and Open Heart Surgery (Coronary Bypass With or Without Another Procedure). <i>American Journal of Cardiology</i> , 2005, 96, 519-523.	0.7	89
54	Relationship of Body Mass Index With Total Mortality, Cardiovascular Mortality, and Myocardial Infarction After Coronary Revascularization: Evidence From a Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1080-1100.	1.4	88

#	ARTICLE	IF	CITATIONS
55	2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1001-1019.	0.7	85
56	Early intravenous beta-blockers in patients with acute coronary syndrome—A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 915-921.	0.8	84
57	Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006, 151, 1123-1128.	1.2	78
58	Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2015, 36, 2373-2380.	1.0	70
59	Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis. <i>Clinical Cardiology</i> , 2017, 40, 73-81.	0.7	69
60	Prognostic implication of troponin I elevation after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2003, 91, 1272-1274.	0.7	67
61	Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials. <i>International Journal of Cardiology</i> , 2015, 179, 279-287.	0.8	67
62	Role of Niacin in Current Clinical Practice: A Systematic Review. <i>American Journal of Medicine</i> , 2017, 130, 173-187.	0.6	66
63	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2218-2261.	1.2	66
64	Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials. <i>Canadian Journal of Cardiology</i> , 2014, 30, 888-897.	0.8	65
65	Carotid artery intimal-medial thickness: Indicator of atherosclerotic burden and response to risk factor modification. <i>American Heart Journal</i> , 2002, 144, 753-759.	1.2	65
66	New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons. <i>PLoS ONE</i> , 2013, 8, e77694.	1.1	65
67	Alteration of Cardiac Collagen Phenotypes in Hypertensive Hypertrophy: Role of Blood Pressure. <i>Journal of Molecular and Cellular Cardiology</i> , 1993, 25, 185-196.	0.9	64
68	Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1262-1273.	1.1	60
69	Perioperative Cardiac Assessment for Noncardiac Surgery. <i>Circulation</i> , 2003, 107, 2771-2774.	1.6	59
70	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. <i>International Journal of Cardiology</i> , 2017, 228, 352-358.	0.8	59
71	Carotid artery stenting vs. endarterectomy. <i>European Heart Journal</i> , 2009, 30, 2693-2704.	1.0	58
72	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 54-122.	0.7	57

#	ARTICLE	IF	CITATIONS
73	Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients \geq 40 years old. <i>American Journal of Cardiology</i> , 2003, 92, 1465-1467.	0.7	56
74	Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmural revascularization. <i>American Heart Journal</i> , 2001, 142, 72-74.	1.2	55
75	Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. <i>Journal of Invasive Cardiology</i> , 2006, 18, 405-8.	0.4	54
76	Management of Transplant Renal Artery Stenosis. <i>Angiology</i> , 2011, 62, 219-224.	0.8	52
77	Prognostic Value of Transient and Sustained Increase in In-Hospital Creatinine on Outcomes of Patients Admitted With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2007, 99, 939-942.	0.7	51
78	Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. <i>Thrombosis and Haemostasis</i> , 2017, 117, 246-251.	1.8	51
79	Treatment Discontinuations With New Oral Agents for Long-term Anticoagulation: Insights From a Meta-analysis of 18 Randomized Trials Including 101,801 Patients. <i>Mayo Clinic Proceedings</i> , 2014, 89, 896-907.	1.4	50
80	Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates. <i>American Journal of Cardiology</i> , 2014, 113, 1815-1821.	0.7	50
81	Effects of cilostazol in patients with Raynaud's syndrome. <i>American Journal of Cardiology</i> , 2003, 92, 1310-1315.	0.7	49
82	Cardiac Overexpression of Myotrophin Triggers Myocardial Hypertrophy and Heart Failure in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 20422-20434.	1.6	47
83	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1023-1082.	0.7	46
84	Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 474-480.	1.4	45
85	Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: A meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 203-212.	0.7	45
86	Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). <i>American Heart Journal</i> , 2002, 144, 995-1002.	1.2	44
87	Percutaneous Treatment for Pacemaker-Associated Superior Vena Cava Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 1628-1633.	0.5	44
88	Rivaroxaban and risk of myocardial infarction. <i>Coronary Artery Disease</i> , 2013, 24, 628-635.	0.3	44
89	Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials. <i>Drugs</i> , 2013, 73, 1171-1182.	4.9	42
90	Timing and Route of Amiodarone for Prevention of Postoperative Atrial Fibrillation after Cardiac Surgery: A Network Regression Meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 1017-1023.	0.5	42

#	ARTICLE	IF	CITATIONS
91	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement. Part II. Mitral Valve. Journal of the American College of Cardiology, 2014, 64, 1515-1526.	1.2	42
92	Critical and Acute Limb Ischemia. Angiology, 2014, 65, 137-146.	0.8	41
93	Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	41
94	Aortic Dissection—An Update. Current Problems in Cardiology, 2005, 30, 287-325.	1.1	40
95	Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 335-345.	2.2	39
96	Contemporary management of concomitant carotid and coronary artery disease. Heart, 2011, 97, 175-180.	1.2	39
97	Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1639-1648.	1.1	39
98	Implementation of the ACC/AHA Guidelines for Preoperative Cardiac Risk Assessment in a General Medicine Preoperative Clinic: Improving Efficiency and Preserving Outcomes. Cardiology, 2005, 103, 24-29.	0.6	38
99	Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists. American Journal of Medicine, 2012, 125, 817-825.	0.6	37
100	Cardiovascular safety profile of currently available diabetic drugs. Ochsner Journal, 2014, 14, 616-32.	0.5	37
101	Implications of Periaortic Hematoma in Patients With Acute Aortic Dissection (from the International Tj ETQq1 1 0,784314 rgBT /Over	0.7	36
102	Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2015, 4, .	1.6	36
103	Feasibility of simultaneous bilateral carotid artery stenting. Catheterization and Cardiovascular Interventions, 2004, 61, 437-442.	0.7	35
104	Meta-Analysis of Cardiovascular Outcomes With Dronedarone in Patients With Atrial Fibrillation or Heart Failure. American Journal of Cardiology, 2012, 110, 607-613.	0.7	35
105	Effect of Contralateral Occlusion on Long-Term Efficacy of Endarterectomy in the Asymptomatic Carotid Atherosclerosis Study (ACAS). Stroke, 2001, 32, 1443-1448.	1.0	34
106	Development of a multicenter peripheral arterial interventional database: The PVD-QI2. American Heart Journal, 2005, 149, 1003-1008.	1.2	34
107	Outcome of Multivessel Coronary Intervention in the Contemporary Percutaneous Revascularization Era. American Journal of Cardiology, 2006, 97, 1585-1590.	0.7	34
108	Peroxisome proliferator-activated receptor Î³ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study. American Heart Journal, 2007, 154, 137-143.	1.2	31

#	ARTICLE	IF	CITATIONS
109	Peripheral Arterial Disease: Considerations in Risks, Diagnosis, and Treatment. Journal of the National Medical Association, 2009, 101, 999-1008.	0.6	31
110	Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine. Journal of the American College of Cardiology, 2012, 59, 1833-1847.	1.2	31
111	Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of Thrombosis and Thrombolysis, 2013, 36, 223-232.	1.0	31
112	Myocardial Infarction With Nonobstructive Coronary Arteries: A Call for Individualized Treatment. Journal of the American Heart Association, 2019, 8, e013361.	1.6	31
113	An Updated Review on Myocardial Bridging. Cardiovascular Revascularization Medicine, 2020, 21, 1169-1179.	0.3	31
114	Improvement in Right Ventricular Systolic Function After Surgical Correction of Isolated Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2000, 13, 650-654.	1.2	30
115	Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk. Current Vascular Pharmacology, 2016, 14, 415-425.	0.8	30
116	Meta-Analysis of Global Left Ventricular Function Comparing Multidetector Computed Tomography With Cardiac Magnetic Resonance Imaging. American Journal of Cardiology, 2014, 113, 731-738.	0.7	29
117	Drug-eluting stents in patients with end-stage renal disease: Meta-analysis and systematic review of the literature. Catheterization and Cardiovascular Interventions, 2010, 76, 942-948.	0.7	28
118	Pharmacogenomics in cardiovascular diseases. Progress in Cardiovascular Diseases, 2002, 44, 479-498.	1.6	27
119	Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors. Arthritis Research, 2003, 5, 8.	2.0	27
120	Remote ischemic preconditioning in patients undergoing cardiovascular surgery: Evidence from a meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 221, 34-41.	0.8	26
121	Polypharmacy in Cardiovascular Medicine: Problems and Promises!. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 15, 31-39.	0.4	26
122	Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. American Journal of Cardiology, 2004, 94, 1166-1168.	0.7	25
123	Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal, 2005, 26, 2524-2528.	1.0	25
124	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part III: Pulmonic Valve. Journal of the American College of Cardiology, 2015, 65, 2556-2563.	1.2	25
125	Epidemiology and Adverse Consequences of Hookah/Waterpipe Use: A Systematic Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2019, 17, 82-93.	0.4	25
126	Renal artery end-diastolic velocity and renal artery resistance index as predictors of outcome after renal stenting. American Journal of Cardiology, 2001, 88, 1064-1066.	0.7	24

#	ARTICLE	IF	CITATIONS
127	Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2016, 32, 814-823.	0.8	24
128	Carotid brachytherapy for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 86-92.	0.7	23
129	Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein ≥ 80 mg/dl. <i>American Journal of Cardiology</i> , 2005, 96, 1491-1493.	0.7	23
130	COCATS 4 Task Force 1: Training in Ambulatory, Consultative, and Longitudinal Cardiovascular Care. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1734-1753.	1.2	23
131	Endovascular treatment of carotid artery aneurysms with stent grafts. <i>Journal of Invasive Cardiology</i> , 2002, 14, 269-72.	0.4	23
132	MTHFR A1298C polymorphism is associated with cardiovascular risk in end stage renal disease in North Indians. <i>Molecular and Cellular Biochemistry</i> , 2008, 308, 43-50.	1.4	22
133	Coronary, Peripheral and Cerebrovascular Disease: a Complex Relationship. <i>Herz</i> , 2008, 33, 475-480.	0.4	22
134	HIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients. <i>Journal of Immunology</i> , 2016, 196, 1768-1779.	0.4	22
135	Meta-Analysis of the Relation of Baseline Right Ventricular Function to Response to Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2016, 117, 1315-1321.	0.7	21
136	Women, the menopause, hormone replacement therapy and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 432-438.	0.8	20
137	Cardiac Trauma. <i>Angiology</i> , 2016, 67, 896-901.	0.8	20
138	Device Thrombosis with Bioresorbable Scaffolds. <i>New England Journal of Medicine</i> , 2017, 376, 2388-2389.	13.9	20
139	Prognostic significance of an elevated creatine kinase in the absence of an elevated troponin I during an acute coronary syndrome. <i>American Journal of Cardiology</i> , 2003, 92, 1442-1444.	0.7	19
140	Long-term prognostic implication of extracardiac vascular disease in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2003, 92, 964-966.	0.7	19
141	Basic cerebral anatomy for the carotid interventionalist: The intracranial and extracranial vessels. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 104-111.	0.7	19
142	CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis. <i>Scientific Reports</i> , 2017, 7, 232.	1.6	19
143	Heparin-induced thrombocytopenia and cardiovascular diseases. <i>American Heart Journal</i> , 2006, 152, 19-26.	1.2	18
144	The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries. <i>Current Vascular Pharmacology</i> , 2010, 8, 293-300.	0.8	18

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of Bivalirudin with Glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. <i>Indian Heart Journal</i> , 2012, 64, 444-448.	0.2	18
146	Management of refractory angina in the contemporary era. <i>European Heart Journal</i> , 2013, 34, 2655-2657.	1.0	18
147	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	18
148	The role of low-molecularâ€‘weight heparin in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 139-156.	1.6	17
149	Impact of extracardiac vascular disease on acute prognosis in patients who undergo percutaneous coronary interventions (data from the Blue Cross & Blue Shield of Michigan Cardiovascular) Tj ETQq1 1 0.784314 r0B7 /Overl0ck 10 T 5	0.7	17
150	Meta-Analysis of Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Unprotected Left Main Coronaryâ€‘Narrowing. <i>American Journal of Cardiology</i> , 2017, 119, 1746-1752.	0.7	17
151	Treatmentâ€‘risk paradox in acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 3807-3809.	1.0	17
152	Gamut of Cardiac Manifestations and Complications of COVID-19: A Contemporary Review. <i>Journal of Investigative Medicine</i> , 2020, 68, 1334-1340.	0.7	17
153	Quantification of Myotrophin From Spontaneously Hypertensive and Normal Rat Hearts. <i>Circulation Research</i> , 1995, 76, 1020-1027.	2.0	17
154	A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 105-112.	0.4	17
155	Current role of emboli protection devices in percutaneous coronary and vascular interventions. <i>American Heart Journal</i> , 2009, 157, 263-270.	1.2	16
156	Peripheral Arterial Disease. <i>Angiology</i> , 2013, 64, 569-571.	0.8	16
157	Portopulmonary hypertension: An update. <i>Respirology</i> , 2015, 20, 235-242.	1.3	16
158	Role of Vasodilator Testing in Pulmonary Hypertension. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 425-433.	1.6	16
159	Risk of contrastâ€‘induced acute kidney injury in STâ€‘elevation myocardial infarction patients undergoing multiâ€‘vessel interventionâ€‘metaâ€‘analysis of randomized trials and risk prediction modeling study using observational data. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 205-212.	0.7	16
160	Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials. <i>International Journal of Cardiology</i> , 2017, 227, 617-624.	0.8	16
161	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease:. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007244.	1.4	16
162	PAR-1 antagonists: current state of evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 1-9.	1.0	15

#	ARTICLE	IF	CITATIONS
163	Etiologies, trends, and predictors of readmission in ST-elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 905-914.	0.7	15
164	Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. <i>PLoS ONE</i> , 2020, 15, e0238262.	1.1	15
165	Coronary Calcium Risk Score and Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2020, 19, 280-284.	0.8	15
166	Drug-drug interactions involving antiplatelet agents. <i>European Heart Journal</i> , 2003, 24, 1707-1709.	1.0	14
167	Effectiveness of PCI for non-acute coronary artery disease. <i>Lancet, The</i> , 2009, 373, 870-872.	6.3	14
168	Role of Baseline Echocardiography in Preoperative Management of Liver Transplant Candidates. <i>American Journal of Cardiology</i> , 2013, 111, 1231.	0.7	14
169	Brugada Phenocopy in Concomitant Ethanol and Heroin Overdose. , 2015, 20, 87-90.		14
170	Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 500-507.	1.6	14
171	Intervention strategies for multi-vessel disease in patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2015, 179, 225-227.	0.8	13
172	Potential role of systemic thrombolysis in acute submassive intermediate risk pulmonary embolism: review and future perspectives. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 103-110.	1.0	13
173	Superficial femoral artery occlusion: nitinol stents achieve better flow and reduce the need for medications than balloon angioplasty alone. <i>Journal of Invasive Cardiology</i> , 2003, 15, 198-200.	0.4	13
174	Atherogenic Vascular Stiffness and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 919.	3.8	12
175	Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 187, 345-353.	0.8	12
176	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. <i>International Journal of Cardiology</i> , 2017, 229, 82-89.	0.8	12
177	Ultrasound-Assisted Catheter-Directed Thrombolysis: A Novel and Promising Endovascular Therapeutic Modality for Intermediate-Risk Pulmonary Embolism. <i>Angiology</i> , 2017, 68, 494-501.	0.8	12
178	SCAI publications committee manual of standard operating procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 145-155.	0.7	12
179	Associations between Combined Influenza and Pneumococcal Pneumonia Vaccination and Cardiovascular Outcomes. <i>Cardiology</i> , 2021, 146, 772-780.	0.6	12
180	Liver abnormalities in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	12

#	ARTICLE	IF	CITATIONS
181	Extracranial Vertebral Artery Intervention. <i>Journal of Interventional Cardiology</i> , 2007, 20, 409-416.	0.5	11
182	Nonsteroidal Anti-Inflammatory Drugs and the Heart: What Is the Danger?. <i>Congestive Heart Failure</i> , 2008, 14, 75-82.	2.0	11
183	Safety and efficacy of radial versus femoral access for rotational Atherectomy: A systematic review and meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 241-247.	0.3	11
184	Outcomes of rotational atherectomy versus orbital atherectomy for the treatment of heavily calcified coronary stenosis: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 884-892.	0.7	11
185	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2344-2349.	1.1	11
186	Coronary, peripheral and cerebrovascular disease: a complex relationship. <i>Journal of the Indian Medical Association</i> , 2010, 108, 292-4, 296.	0.2	11
187	Endovascular Treatment of Carotid Artery Aneurysms With Covered Stents. <i>Circulation</i> , 2001, 104, 2995-2995.	1.6	10
188	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. <i>American Journal of Cardiology</i> , 2002, 90, 1198-1203.	0.7	10
189	Pharmacogenomics in cardiovascular diseases. <i>Current Problems in Cardiology</i> , 2003, 28, 317-347.	1.1	10
190	Pharmaceutical advertising versus research spending: are profits more important than patients?. <i>American Heart Journal</i> , 2003, 146, 563-564.	1.2	10
191	Hormone Replacement Therapy and Secondary Cardiovascular Prevention: A Meta-Analysis of Randomized Trials. <i>Cardiology</i> , 2005, 104, 143-147.	0.6	10
192	Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. <i>Critical Care Clinics</i> , 2007, 23, 709-735.	1.0	10
193	Effectiveness of Drug-Eluting Stents in Real-World Patients. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 454-5.	3.8	10
194	Risk Factors in First Presentation Acute Coronary Syndromes (ACS): How Do We Move From Population to Individualized Risk Prediction?. <i>Angiology</i> , 2009, 60, 663-667.	0.8	10
195	Clinical Perspectives on the Role of Anti-Platelet and Statin Therapy in Patients with Vascular Diseases. <i>Current Vascular Pharmacology</i> , 2003, 1, 329-333.	0.8	10
196	Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. <i>American Heart Journal</i> , 2000, 140, S136-S142.	1.2	9
197	Monitoring Antiplatelet Therapy. <i>Clinical Pharmacokinetics</i> , 2000, 39, 445-458.	1.6	9
198	Glycoprotein IIb/IIIa Receptor Inhibitors in 2008: Do They Still Have a Role?. <i>Journal of Interventional Cardiology</i> , 2008, 21, 118-121.	0.5	9

#	ARTICLE	IF	CITATIONS
199	Contemporary Management of Infrapopliteal Peripheral Arterial Disease. <i>Angiology</i> , 2011, 62, 490-499.	0.8	9
200	Developing an action plan for patient radiation safety in adult cardiovascular medicine. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 534-550.	1.4	9
201	Mortality and major adverse cardiovascular events after transcatheter aortic valve replacement using Edwards valve versus CoreValve: A meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 24-33.	0.3	9
202	Entresto, a New Panacea for Heart Failure?. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2018, 16, 5-11.	0.4	9
203	Pulmonary Embolism Response Teams: Pursuing Excellence in the Care for Venous Thromboembolism. <i>Archives of Medical Research</i> , 2019, 50, 257-258.	1.5	9
204	In AF with recent ACS or PCI, apixaban reduced bleeding vs VKAs; aspirin increased bleeding vs placebo. <i>Annals of Internal Medicine</i> , 2019, 171, JC7.	2.0	9
205	Coronary Revascularization in the United States—Patient Characteristics and Outcomes in 2020. <i>JAMA Network Open</i> , 2020, 3, e1921322.	2.8	9
206	Congenital Absence of Left Circumflex Presenting After an Emotional Stressor. <i>Polski Przegląd Radiologii i Medycyny Nuklearnej</i> , 2015, 80, 529-531.	1.0	9
207	Current clinical perspectives on myocardial angiogenesis. <i>Molecular and Cellular Biochemistry</i> , 2004, 264, 157-167.	1.4	8
208	Brachytherapy for In-Stent Restenosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1307.	3.8	8
209	Glucose Levels and Depression in Hispanic Patients Admitted to the Cardiovascular Intensive Care Unit. <i>Angiology</i> , 2015, 66, 57-64.	0.8	8
210	Duration of dual antiplatelet therapy after various drug-eluting stent implantation. <i>International Journal of Cardiology</i> , 2016, 215, 157-166.	0.8	8
211	Pulmonary embolism response teams in the challenging era of venous thromboembolism associated with COVID-19. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 898-899.	0.9	8
212	Pulmonary Hypertension secondary to Left Heart Disease. <i>Current Vascular Pharmacology</i> , 2018, 16, 555-560.	0.8	8
213	Urinary tract infection in renal transplant recipients at a tertiary care center in India. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2018, 29, 361.	0.4	8
214	Mycotic Intracranial Aneurysm Secondary to Left Ventricular Assist Device Infection. <i>Journal of Vascular and Interventional Neurology</i> , 2017, 9, 23-25.	1.1	8
215	Applications of anti-platelet monitoring in catheterization laboratory. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 293-301.	1.0	7
216	Percutaneous treatment for carotid stenosis. <i>Cardiology Clinics</i> , 2002, 20, 589-597.	0.9	7

#	ARTICLE	IF	CITATIONS
217	Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?. <i>American Heart Journal</i> , 2004, 148, 371-377.	1.2	7
218	Current strategies with high-dose tirofiban. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 275-280.	1.5	7
219	Reperfusion Strategies for Acute Ischemic Stroke. <i>Angiology</i> , 2012, 63, 289-296.	0.8	7
220	Depression as a Predictor of Length of Stay in Patients Admitted to the Cardiovascular Intensive Care Unit at a University Medical Center. <i>Angiology</i> , 2014, 65, 580-584.	0.8	7
221	Obesity Paradox in Contemporary Cardiology Practice. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1293-1294.	1.1	7
222	SCAI/ACVP expert consensus statement on cardiovascular catheterization laboratory economics: If the cath lab is your home you should understand its finances. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 123-135.	0.7	7
223	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 769.	1.0	7
224	Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke – An Updated Comprehensive Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 687-694.	0.3	7
225	Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 23-29.	0.2	7
226	Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 11, 151-154.	1.0	6
227	Optimal treatment for in-stent restenosis after BMS-DES, coated balloon, or scalpel?. <i>European Heart Journal</i> , 2008, 29, 1595-1596.	1.0	6
228	Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease. <i>Current Vascular Pharmacology</i> , 2010, 8, 93-101.	0.8	6
229	Evidence-based management of carotid artery disease. <i>International Journal of Angiology</i> , 2010, 19, e21-e24.	0.2	6
230	Current Management of Peripheral Vascular Disease: Where is the Evidence?. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 128-136.	0.4	6
231	Implementation of Evidence-Based Therapies for Myocardial Infarction and Survival. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1710.	3.8	6
232	Reverse Takotsubo Cardiomyopathy with Use of Male Enhancers. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 78-80.	0.2	6
233	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1084-1093.	1.4	6
234	Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Acute Myocardial Infarction with Cardiogenic Shock: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 956-964.	0.3	6

#	ARTICLE	IF	CITATIONS
235	Perioperative Acute Pulmonary Embolism: A Concise Review with Emphasis on Multidisciplinary Approach. <i>International Journal of Angiology</i> , 2020, 29, 183-188.	0.2	6
236	Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 791-796.	1.0	6
237	Management of Chronic Total Occlusion of Coronary Artery. <i>International Journal of Angiology</i> , 2021, 30, 048-052.	0.2	6
238	Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions. <i>Current Vascular Pharmacology</i> , 2013, 11, 507-513.	0.8	6
239	A Review of the Current Role of Blood Clotting Analyzers in Clinical Practice. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2018, 17, 167-179.	0.2	6
240	Gene Therapy in Cardiovascular Diseases. <i>Current Gene Therapy</i> , 2002, 2, 427-435.	0.9	5
241	Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 400-414.	1.3	5
242	Successful pharmacomechanical intervention with ultrasonic-accelerated thrombolytic catheter for massive pulmonary embolism. <i>Indian Heart Journal</i> , 2013, 65, 699-702.	0.2	5
243	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement: Part II. Mitral Valve. <i>Annals of Thoracic Surgery</i> , 2014, 98, 765-777.	0.7	5
244	Double right coronary artery and its clinical significance: Review of the literature. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 632-635.	0.3	5
245	Guide of Hypertensive Crisis Pharmacotherapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2017, 17, 52-57.	0.2	5
246	Minimizing Distal Embolization During Carotid Artery Stenting. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 404-405.	1.1	5
247	Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 758-767.	0.3	5
248	Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A Comprehensive Meta-analysis. <i>Current Problems in Cardiology</i> , 2021, 46, 100695.	1.1	5
249	Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review. <i>Current Vascular Pharmacology</i> , 2022, 20, 46-51.	0.8	5
250	Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 150, 15-23.	0.7	5
251	Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 194-202.	0.4	5
252	Renal artery stenosis: who to screen and how to treat?. <i>ACC Current Journal Review</i> , 2003, 12, 70-75.	0.1	4

#	ARTICLE	IF	CITATIONS
253	Optimizing management of patients with coronary artery disease: how do we get there?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1147-1149.	1.0	4
254	Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. Vascular Health and Risk Management, 2009, 5, 275.	1.0	4
255	Optimal Management of Hypertension in patients with Ischemic Heart Disease. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 198-205.	0.4	4
256	Natural History of Saphenous Vein Grafts. Interventional Cardiology Clinics, 2013, 2, 251-258.	0.2	4
257	Prevalence and Predictors of Left Ventricular Diastolic Dysfunction in a Hispanic Patient Population. International Journal of Angiology, 2013, 22, 229-234.	0.2	4
258	Cardiopulmonary hemodynamics for accurate diagnosis of portopulmonary hypertension: A redefinition to consider. Hepatology, 2015, 61, 733-734.	3.6	4
259	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, Part III: Pulmonic valve. Catheterization and Cardiovascular Interventions, 2015, 86, 85-93.	0.7	4
260	Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR). Journal of Thrombosis and Thrombolysis, 2015, 39, 467-473.	1.0	4
261	Is multivessel intervention in STâ€elevation myocardial infarction associated with early harm? Insights from observational data. Catheterization and Cardiovascular Interventions, 2016, 88, 697-707.	0.7	4
262	Paclitaxel-Coated Balloons: Review of a Promising Interventional Approach to Preventing Restenosis in Femoropopliteal Arteries. International Journal of Angiology, 2016, 25, 075-080.	0.2	4
263	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. Current Problems in Cardiology, 2018, 43, 191-216.	1.1	4
264	Clinical characteristics and outcomes of patients requiring prolonged inotropes after left ventricular assist device implantation. Artificial Organs, 2020, 44, E382-E393.	1.0	4
265	Early Post-Percutaneous Coronary Intervention Chest Pain: A Nationwide Survey on Interventional Cardiologists' Perspective. Cardiovascular Revascularization Medicine, 2020, 21, 1517-1522.	0.3	4
266	Management of Cocaine-Associated Nonâ€eST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2021, 14, 637-638.	1.1	4
267	Impact and Role of Pulmonary Embolism Response Teams in Venous Thromboembolism Associated with Covid-19. Journal of Investigative Medicine, 2021, 69, 1153-1155.	0.7	4
268	Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 1-6.	0.2	4
269	Silent myocardial infarction and risk of heart failure. Annals of Translational Medicine, 2018, 6, S35-S35.	0.7	4
270	The Role of Percutaneous Coronary Intervention in the Treatment of Chronic Total Occlusions: Rationale and Review of the Literature. Current Vascular Pharmacology, 2019, 17, 278-290.	0.8	4

#	ARTICLE	IF	CITATIONS
271	Contemporary Review of Drugs Used to Treat Obesity. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2014, 11, 272-280.	0.4	4
272	Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option. Cardiovascular & Hematological Disorders Drug Targets, 2017, 17, 80-85.	0.2	4
273	Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Thrombosis and Haemostasis, 2006, 96, 407-12.	1.8	4
274	Current Role of Antithrombotic Agents in the Treatment of Acute Coronary Syndromes. Seminars in Thrombosis and Hemostasis, 2004, 30, 627-632.	1.5	3
275	The Use of Antithrombotics for Acute Coronary Syndromes in the Emergency Department: Considerations and Impact. Progress in Cardiovascular Diseases, 2007, 50, 167-180.	1.6	3
276	Current Endovascular Treatment of Peripheral Arterial Disease. Progress in Cardiovascular Nursing, 2007, 22, 31-37.	0.5	3
277	Platelet glycoprotein IIb/IIIa receptor inhibitors—end of an era?. European Heart Journal, 2008, 29, 429-431.	1.0	3
278	Current Status of Carotid Stenting. Current Vascular Pharmacology, 2008, 6, 143-147.	0.8	3
279	Chronic total occlusions in non-infarct-related arteries. European Heart Journal, 2012, 33, 695-697.	1.0	3
280	Clinical profiles and outcomes of acute aortic dissection in a predominantly Hispanic population. Medical Science Monitor, 2014, 20, 747-751.	0.5	3
281	G Protein-Coupled Receptors “ Potential Roles in Clinical Pharmacology. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2014, 12, 29-33.	0.4	3
282	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement. Part II. Mitral valve. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 387-400.	0.4	3
283	Effect of cardiac resynchronization therapy on right ventricular function. International Journal of Cardiology, 2016, 209, 34-36.	0.8	3
284	Incidence of Renal Failure Requiring Hemodialysis Following Transcatheter Aortic Valve Replacement. American Journal of the Medical Sciences, 2016, 352, 306-313.	0.4	3
285	Valvular performance and aortic regurgitation following transcatheter aortic valve replacement using Edwards valve versus CoreValve for severe aortic stenosis: A Meta-analysis. Cardiovascular Revascularization Medicine, 2016, 17, 248-255.	0.3	3
286	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. Current Problems in Cardiology, 2018, 43, 217-231.	1.1	3
287	Coronary lesion complexity and the benefit of potent platelet inhibition after percutaneous coronary intervention. European Heart Journal, 2018, 39, 4122-4124.	1.0	3
288	Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. Cardiovascular & Hematological Disorders Drug Targets, 2020, 20, 3-15.	0.2	3

#	ARTICLE	IF	CITATIONS
289	After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleeding. <i>Annals of Internal Medicine</i> , 2020, 173, JC22.	2.0	3
290	High Flow Nasal Cannula Oxygenation Successfully Used as Bridge Therapy for Systemic Thrombolysis in COVID-19 Associated Intermediate-high Risk Pulmonary Embolism. <i>Current Problems in Cardiology</i> , 2022, 47, 101000.	1.1	3
291	Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs). <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 14, 76-81.	0.4	3
292	Improving quality of cardiovascular care in the real world: how can we remove the barriers?. <i>American Journal of Managed Care</i> , 2004, 10, 471-2.	0.8	3
293	Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. <i>Current Opinion in Cardiology</i> , 2022, Publish Ahead of Print, .	0.8	3
294	Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients. <i>Cardiology Clinics</i> , 2005, 23, 185-191.	0.9	2
295	Pharmacotherapy of acute coronary syndrome: the AQUIITY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 369-380.	0.9	2
296	Spatial distribution of coronary artery thromboses in patients with chronic kidney disease: implications for diagnosis and treatment. <i>Kidney International</i> , 2009, 75, 7-9.	2.6	2
297	Antithrombotics and stent type for primary PCI. <i>Lancet, The</i> , 2011, 377, 2154-2156.	6.3	2
298	Current Approaches to Prevention of Contrast Induced Acute Kidney Injury. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 247-252.	0.4	2
299	Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular) <i>Tj ETQq1 1 0.784314 rgBT /Overloc</i>	0.8	2
300	Traditional NSAIDs and coxibs: is one better than the other?. <i>European Heart Journal</i> , 2017, 38, ehw507.	1.0	2
301	Role of Vorapaxar After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2016, 117, 1059-1064.	0.7	2
302	One-Year Survival is Not Affected by Gastrointestinal Bleeding After Percutaneous Coronary Interventions. <i>American Journal of the Medical Sciences</i> , 2017, 353, 381-386.	0.4	2
303	Underutilization of Cardiac Therapies in Patients with Acute Ischemic Stroke and Elevated Troponin. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2019, 17, 144-151.	0.4	2
304	Tailoring strategies to optimize ischaemic benefit vs. bleeding risk in individuals post-myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 844-846.	1.0	2
305	Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2020, 22, 126.	1.3	2
306	Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk. <i>Heart International</i> , 2021, 15, 26.	0.4	2

#	ARTICLE	IF	CITATIONS
307	The Effect of Clinical Depression on Post-TAVI All-Cause Mortality. <i>American Journal of Cardiology</i> , 2021, 155, 151-152.	0.7	2
308	Endovascular Revascularization and Outcomes in Critical Limb Ischemia. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1937-1939.	1.1	2
309	Serelaxin: New Investigational Treatment in Acute Heart Failure. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 243-248.	0.4	2
310	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 281-288.	0.4	2
311	Coronary revascularization prior to elective vascular surgery: Does it reduce cardiac risk?. <i>Journal of Vascular Surgery</i> , 2002, 36, 644-645.	0.6	1
312	Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes. <i>Current Cardiology Reports</i> , 2003, 5, 289-295.	1.3	1
313	Role of Emboli protection devices in native coronary and saphenous vein graft percutaneous interventions. <i>ACC Current Journal Review</i> , 2004, 13, 32-35.	0.1	1
314	Clopidogrel-Proton Pump Inhibitor Interaction: A Primer for Clinicians. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2010, 10, 66-72.	0.2	1
315	Response to: Brugada Phenocopy: Morphological Classification and Importance of Provocative Testing. <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 606-606.	0.5	1
316	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, part III. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, e71-e78.	0.4	1
317	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part III: Pulmonic Valve. <i>Annals of Thoracic Surgery</i> , 2015, 99, 1857-1864.	0.7	1
318	Impact of intraprocedural thrombotic events on short- and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. <i>International Journal of Cardiology</i> , 2016, 202, 469-476.	0.8	1
319	Prior Coronary Revascularization and Risk of Noncardiac Surgery. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 339-341.	1.1	1
320	A rare presentation of nephrotic syndrome. <i>CEN Case Reports</i> , 2017, 6, 161-163.	0.5	1
321	Coronary Angiography Challenges After Transcatheter Aortic Valve Replacement in Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2020, 9, e017409.	1.6	1
322	Outcomes Following Percutaneous Coronary Intervention Before, During, and After Transition to a Default Transradial Approach at a Veterans Affairs Medical Center. <i>Angiology</i> , 2020, 71, 602-608.	0.8	1
323	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. <i>Annals of Translational Medicine</i> , 2021, 9, 523-523.	0.7	1
324	Pulmonary Thromboembolism as a Complication of Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>Medical Science Case Reports</i> , 0, 2, 33-37.	0.0	1

#	ARTICLE	IF	CITATIONS
325	Eisenmenger Syndrome: Recent Advances in Pharmacotherapy. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2014, 11, 289-296.	0.4	1
326	Myopericarditis as a complication of nonspecific colitis. American Journal of Case Reports, 2014, 15, 82-84.	0.3	1
327	Is Percutaneous Coronary Intervention Now the Default Revascularization Strategy for Unprotected Left Main Coronary Artery Stenosis?. Journal of the American Heart Association, 2022, 11, e025748.	1.6	1
328	Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction. Cardiovascular & Hematological Disorders Drug Targets, 2022, 22, 87-95.	0.2	1
329	Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on One-Year Event-Free survival. American Journal of Cardiology, 2003, 91, 587-590.	0.7	0
330	Current Perspectives on Hypertension in Asian Indians. Current Hypertension Reviews, 2007, 3, 264-269.	0.5	0
331	Unraveling the Genetic Predisposition for Aortic Aneurysms: Is it Time for Tailored Medicine?. American Journal of Hypertension, 2008, 21, 967-967.	1.0	0
332	Antithrombotic Agents for Acute Coronary Syndromes. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2008, 6, 130-141.	0.4	0
333	Percutaneous versus surgical revascularization for symptomatic carotid artery disease. Current Cardiology Reports, 2009, 11, 384-390.	1.3	0
334	The high cost of nonadherence after percutaneous coronary intervention—Can health care reform solve this problem?. American Heart Journal, 2009, 158, 506-508.	1.2	0
335	Perfluorooctanoic Acid Exposure and Cardiovascular Disease. Archives of Internal Medicine, 2012, 172, 1403.	4.3	0
336	Patient-Level vs Group-Level Data to Adjust Meta-analysis on Transfusion and Mortality—Reply. JAMA Internal Medicine, 2013, 173, 1157.	2.6	0
337	After drug-eluting stent placement, 6 months of dual antiplatelet therapy was noninferior to 12 months. Annals of Internal Medicine, 2015, 162, JC6.	2.0	0
338	Review: After coronary DES placement, longer vs shorter DAPT increases major bleeding and death and reduces MI. Annals of Internal Medicine, 2015, 163, JC6.	2.0	0
339	Reply From the Author. Angiology, 2015, 66, 493-493.	0.8	0
340	Reply. JACC: Cardiovascular Interventions, 2016, 9, 2459-2460.	1.1	0
341	Current role of β -blockers after MI in patients without HF. Nature Reviews Cardiology, 2016, 13, 699-700.	6.1	0
342	Renal artery revascularisation: can we predict who benefits?. Heart Asia, 2017, 9, e010951.	1.1	0

#	ARTICLE	IF	CITATIONS
343	A rare cause of chest pain: Cardiac synovial sarcoma. Egyptian Journal of Radiology and Nuclear Medicine, 2017, 48, 869-871.	0.3	0
344	Usefulness of left ventricular mass change to predict progression of renal dysfunction in Hispanics. Baylor University Medical Center Proceedings, 2018, 31, 20-24.	0.2	0
345	SP733SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION IN RENAL TRANSPLANT RECIPIENTS WITH DIRECT ANTIVIRAL COMBINATION THERAPY. Nephrology Dialysis Transplantation, 2018, 33, i594-i595.	0.4	0
346	Linking the right education to right heart catheterization. Catheterization and Cardiovascular Interventions, 2021, 97, 509-510.	0.7	0
347	Is Colchicine Beneficial for the Prevention of Cardiovascular Events After Myocardial Infarction?. Angiology, 2021, 72, 501-502.	0.8	0
348	Mayâ€Thurner Syndrome in Pregnancy-Associated Venous Thromboembolism. TH Open, 2021, 05, e251-e252.	0.7	0
349	Contrast-induced Nephropathy in Extra-cardiac Vascular Procedures â€ A Call to Action. Current Vascular Pharmacology, 2022, 20, 27-28.	0.8	0
350	Effect SARS-COV-2 on Cases of Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 151, 123-124.	0.7	0
351	Endovascular therapies for Type B Aortic Dissection. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, .	0.2	0
352	Statin Use and Cardiovascular Event/Death Rates After Abdominal Aortic Aneurysm Repair Procedures. Current Vascular Pharmacology, 2022, 20, 313-314.	0.8	0
353	Combination Secondary Prevention Therapies in Vascular Diseases. Vascular Disease Prevention, 2005, 2, 17-19.	0.2	0
354	Abstract 14707: Effect of Cardiac Resynchronization Therapy (CRT) on Right Ventricular (RV) Function. Circulation, 2014, 130, .	1.6	0
355	Chest Pain. JACC: Case Reports, 2021, 3, 1643-1648.	0.3	0
356	Peripheral Arterial Disease in Chronic Kidney Disease: Disease Burden, Outcomes, and Interventional Strategies. , 2020, , 37-68.		0
357	Carotid Artery Pathology in Inflammatory Diseases. American Journal of the Medical Sciences, 2021, , .	0.4	0
358	A 40-year-old female with exertional angina. Journal of Invasive Cardiology, 2005, 17, 185-6.	0.4	0
359	The Association of N-Terminal Pro-Brain Natriuretic Peptide With Time to Clinical Worsening in Hispanic Patients With Pulmonary Arterial Hypertension. Cardiology Research, 2022, 13, 73-80.	0.5	0
360	Association Between Blood Transfusion Treatment Strategy for Acute Coronary Syndromes and Clinical Outcomes: A Meta-analysis of Randomized Clinical Trials. American Journal of Therapeutics, 2024, 31, e84-e87.	0.5	0

#	ARTICLE	IF	CITATIONS
361	Title is missing!. , 2020, 15, e0238262.		0
362	Title is missing!. , 2020, 15, e0238262.		0
363	Title is missing!. , 2020, 15, e0238262.		0
364	Title is missing!. , 2020, 15, e0238262.		0
365	Title is missing!. , 2020, 15, e0238262.		0
366	Title is missing!. , 2020, 15, e0238262.		0